Skip to Content

Elagolix use while Breastfeeding

Drugs containing Elagolix: Oriahnn, Orilissa

Medically reviewed by Drugs.com. Last updated on Aug 6, 2020.

Elagolix Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of elagolix during breastfeeding. Elagolix is 80% protein bound, has a half-life of 4 to 6 hours, and it is a peptide that is likely digested in the infant's gastrointestinal tract, so it is unlikely to reach clinically important levels in infant serum. However, because no information is available on the use of elagolix during breastfeeding caution should be used, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Elagolix

CAS Registry Number

834153-87-6

Drug Class

  • Breast Feeding
  • Lactation
  • GnRH Receptor Antagonists
  • Gonadotropin-Releasing Hormone Antagonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.